Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin-Reference-Cited by-同舟云学术

Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin

Published:2022-04-19 Issue:1 Volume:187 Page:126-127
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Penny Caitlin L.¹^ORCID,Quow Krystina²,Rundle Chandler W.²,Al‐Rohil Rami N.²³,Cardones Adela R.²^ORCID,Kheterpal Meenal K.²^ORCID,Fresco Amber I.²^ORCID

Affiliation:

1. Duke University School of Medicine Durham NC USA

2. Department of Dermatology Duke University Medical Center Durham NC USA

3. Department of Pathology Duke University Medical Center Durham NC USA

Publisher

Oxford University Press (OUP)

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.21022

Reference8 articles.

1. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy

2. Enfortumab Vedotin Antibody–Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models

3. Severe eczematoid and lichenoid eruption with full‐thickness epidermal necrosis developing from metastatic urothelial cancer treated with enfortumab vedotin

4. Cutaneous reactions with enfortumab vedotin: A case series and review of the literature

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nectin-4-directed antibody-drug conjugates (ADCs): Spotlight on preclinical and clinical evidence;Life Sciences;2024-09

2. SDRIFE und bullöse Reaktion nach Behandlung mit Enfortumab Vedotin plus Pembrolizumab: Fallserie;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2024-08

3. Dermatologic toxicities of antibody-drug conjugates;Journal of the American Academy of Dermatology;2024-08

4. Enfortumab vedotin‐induced cutaneous eruption: Ring mitotic figures as a distinctive histopathologic feature;Journal of Cutaneous Pathology;2024-07-15

5. Enfortumab Vedotin Drug Eruption: Cutaneous Adverse Events and Histopathologic Findings;The American Journal of Dermatopathology;2024-06-06